The Zhitong Finance App learned that Haixi New Pharmaceutical (02637) rose by more than 9% in the afternoon. As of press release, it had risen 3.61% to HK$154.9, with a turnover of HK$101.11,000.
According to the news, on November 5, Haixi Pharmaceutical announced that the founder and controlling shareholder of the company, Dr. Kang Xinshan and Ms. Feng Yan (they are spouses and people acting together, collectively referred to as “controlling shareholders”) have voluntarily promised not to sell, transfer or otherwise dispose of any shares of the company directly held by them for a period of 12 months from the date of this announcement (lockdown period) until November 5, 2027 (including that date).
As of the date of this announcement, Dr. Kang Xinshan directly held 12.759 million shares of the company (accounting for about 16.21% of the company's total issued share capital), and Ms. Feng Yan directly held 9.9184 million shares (about 12.60%), for a total of 22.6775 million shares (about 28.81%). The voluntary ban on sale covers all shares directly held by the above controlling shareholders. Dr. Kang Xinshan also held 5 million shares (about 6.35%) indirectly through Xiamen Terry Investment Partnership (limited partnership). Teriwa Investments is a shareholding platform for Group employees. Its limited partnership interests are held by Group employees. Dr. Kang Xinshan is the sole general partner and executive partner, and is entrusted with managing the platform. Such shares are not covered by voluntary anti-sale commitments.